Literature DB >> 31181961

Predictors of isoniazid preventive therapy completion among HIV-infected patients receiving differentiated and non-differentiated HIV care in rural Uganda.

Khai Hoan Tram1, Florence Mwangwa2, Gabriel Chamie3, Mucunguzi Atukunda2, Asiphas Owaraganise2, James Ayieko4, Vivek Jain3, Tamara D Clark3, Dalsone Kwarisiima2,5, Maya L Petersen5,6, Moses R Kamya2,5, Edwin D Charlebois3,7, Diane V Havlir3, Carina Marquez3.   

Abstract

Rates of Isoniazid Preventive Therapy (IPT) completion remain low in programmatic settings in sub-Saharan Africa. Differentiated HIV care models may improve IPT completion by addressing joint barriers to IPT and HIV treatment. However, the impact of differentiated care on IPT completion remains unknown. In a cross-sectional study of people with HIV on antiretroviral therapy in 5 communities in rural Uganda, we compared IPT completion between patients receiving HIV care via a differentiated care model versus a standard HIV care model and assessed multi-level predictors of IPT completion. A total of 103/144 (72%) patients received differentiated care and 85/161 (53%) received standard care completed IPT (p < 0.01). Adjusting for age, gender and community, patients receiving differentiated care had higher odds of completing IPT (aOR: 2.6, 95% CI: 1.5-4.5, p < 0.01). Predictors of IPT completion varied by the care model, and differentiated care modified the positive association between treatment completion and the belief in the efficacy of IPT and the negative association with side-effects. Patients receiving a multi-component differentiated care model had a higher odds of IPT completion than standard care, and the model's impact on health beliefs, social support, and perceived side effects to IPT may underlie this positive association.

Entities:  

Keywords:  East Africa; HIV; Isoniazid preventive therapy; TB prevention; differentiated care

Mesh:

Substances:

Year:  2019        PMID: 31181961      PMCID: PMC6883160          DOI: 10.1080/09540121.2019.1619661

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  28 in total

1.  "It's about my life": facilitators of and barriers to isoniazid preventive therapy completion among people living with HIV in rural South Africa.

Authors:  Karen B Jacobson; Linda Niccolai; Nonhle Mtungwa; Anthony P Moll; Sheela V Shenoi
Journal:  AIDS Care       Date:  2017-02-01

Review 2.  An ecological perspective on health promotion programs.

Authors:  K R McLeroy; D Bibeau; A Steckler; K Glanz
Journal:  Health Educ Q       Date:  1988

3.  Predictors of isoniazid preventive therapy completion among adults newly diagnosed with HIV in rural Malawi.

Authors:  K M Little; M Khundi; G L Barnes; L G Ngwira; A Nkhoma; S Makombe; E L Corbett; R E Chaisson; D W Dowdy
Journal:  Int J Tuberc Lung Dis       Date:  2018-04-01       Impact factor: 2.373

4.  Predictors of adherence to isoniazid preventive therapy in people living with HIV in Ethiopia.

Authors:  H T Ayele; M S M van Mourik; M J M Bonten
Journal:  Int J Tuberc Lung Dis       Date:  2016-10       Impact factor: 2.373

Review 5.  The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis.

Authors:  Hannah Alsdurf; Philip C Hill; Alberto Matteelli; Haileyesus Getahun; Dick Menzies
Journal:  Lancet Infect Dis       Date:  2016-08-10       Impact factor: 25.071

6.  Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial.

Authors:  Anani Badje; Raoul Moh; Delphine Gabillard; Calixte Guéhi; Mathieu Kabran; Jean-Baptiste Ntakpé; Jérôme Le Carrou; Gérard M Kouame; Eric Ouattara; Eugène Messou; Amani Anzian; Albert Minga; Joachim Gnokoro; Patrice Gouesse; Arlette Emieme; Thomas-d'Aquin Toni; Cyprien Rabe; Baba Sidibé; Gustave Nzunetu; Lambert Dohoun; Abo Yao; Synali Kamagate; Solange Amon; Amadou-Barenson Kouame; Aboli Koua; Emmanuel Kouamé; Marcelle Daligou; Denise Hawerlander; Simplice Ackoundzé; Serge Koule; Jonas Séri; Alex Ani; Fassery Dembélé; Fatoumata Koné; Mykayila Oyebi; Nathalie Mbakop; Oyewole Makaila; Carolle Babatunde; Nathaniel Babatunde; Gisèle Bleoué; Mireille Tchoutedjem; Alain-Claude Kouadio; Ghislaine Sena; Sahinou-Yediga Yededji; Sophie Karcher; Christine Rouzioux; Abo Kouame; Rodrigue Assi; Alima Bakayoko; Serge K Domoua; Nina Deschamps; Kakou Aka; Thérèse N'Dri-Yoman; Roger Salamon; Valérie Journot; Hughes Ahibo; Timothée Ouassa; Hervé Menan; André Inwoley; Christine Danel; Serge P Eholié; Xavier Anglaret
Journal:  Lancet Glob Health       Date:  2017-11       Impact factor: 26.763

7.  Improved Retention With 6-Month Clinic Return Intervals for Stable Human Immunodeficiency Virus-Infected Patients in Zambia.

Authors:  Aaloke Mody; Monika Roy; Kombatende Sikombe; Thea Savory; Charles Holmes; Carolyn Bolton-Moore; Nancy Padian; Izukanji Sikazwe; Elvin Geng
Journal:  Clin Infect Dis       Date:  2018-01-06       Impact factor: 9.079

Review 8.  Factors associated with adherence to treatment with isoniazid for the prevention of tuberculosis amongst people living with HIV/AIDS: a systematic review of qualitative data.

Authors:  Titilola Makanjuola; Henock B Taddese; Andrew Booth
Journal:  PLoS One       Date:  2014-02-03       Impact factor: 3.240

9.  Routine implementation of isoniazid preventive therapy in HIV-infected patients in seven pilot sites in Zimbabwe.

Authors:  K C Takarinda; R C Choto; A D Harries; T Mutasa-Apollo; C Chakanyuka-Musanhu
Journal:  Public Health Action       Date:  2017-03-21

10.  Completion of isoniazid preventive therapy among human immunodeficiency virus positive adults in urban Malawi.

Authors:  D Thindwa; P MacPherson; A T Choko; M Khundi; R Sambakunsi; L G Ngwira; T Kalua; E L Webb; E L Corbett
Journal:  Int J Tuberc Lung Dis       Date:  2018-03-01       Impact factor: 2.373

View more
  4 in total

1.  Mixed methods systematic review and metasummary about barriers and facilitators for the implementation of cotrimoxazole and isoniazid-Preventive therapies for people living with HIV.

Authors:  Pia Müller; Luís Velez Lapão
Journal:  PLoS One       Date:  2022-03-01       Impact factor: 3.240

2.  Understanding how community antiretroviral delivery influences engagement in HIV care: a qualitative assessment of the Centralised Chronic Medication Dispensing and Distribution programme in South Africa.

Authors:  Jienchi Dorward; Lindani Msimango; Andrew Gibbs; Hlengiwe Shozi; Sarah Tonkin-Crine; Gail Hayward; Christopher C Butler; Hope Ngobese; Paul K Drain; Nigel Garrett
Journal:  BMJ Open       Date:  2020-05-15       Impact factor: 2.692

Review 3.  Barriers to the Wider Use of Pre-exposure Prophylaxis in the United States: A Narrative Review.

Authors:  Kenneth H Mayer; Allison Agwu; David Malebranche
Journal:  Adv Ther       Date:  2020-03-30       Impact factor: 3.845

4.  Acceptability of Community-Based Tuberculosis Preventive Treatment for People Living with HIV in Zimbabwe.

Authors:  Martin K Msukwa; Munyaradzi P Mapingure; Jennifer M Zech; Tsitsi B Masvawure; Joanne E Mantell; Godfrey Musuka; Tsitsi Apollo; Rodrigo Boccanera; Innocent Chingombe; Clorata Gwanzura; Andrea A Howard; Miriam Rabkin
Journal:  Healthcare (Basel)       Date:  2022-01-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.